The EMVision team consisting of five people, along with the Emu device and the first responder device.

Time is critical for stroke patients. EMVision aims to reduce the burden of stroke and traumatic brain injury. Bringing brain scanners to patients makes it faster to diagnose and treat strokes. And this means better outcomes for patients.

The company’s first device is the emu™. It is a portable bedside brain scanner for hospital use. The First Responder is a lighter, smaller version of the emu™, for use outside hospitals. It weighs around 12 kgs and can fit in a backpack. The scanners are light, fast and easy to use. They use AI, electro-magnetic sensing and imaging, and non-ionising radiation.

Proof it’s a good idea

EMVision has run successful hospital studies with the emu™. This includes trials with more than 300 suspected stroke patients in Melbourne, Sydney and Brisbane. The results showed promising diagnostic accuracy and safety.

This gave the company confidence to go ahead with an international trial which is now in progress. This is for approval from the U.S. Food and Drug Administration.

Finding the funding

CEO Scott Kirkland reached out to the Industry Growth Program for support. The program’s Advisory Service helped refine the strategy for the last stages to develop and commercialise the First Responder and get it out to market.

A $5 million grant will help expand the team and run impactful clinical studies. The company also plans to set up a pilot production line for the First Responder in Sydney to export around the world.

The Industry Growth Program is an attractive source of funding, with an adviser that understands our roadmap.
— Scott Kirkland, CEO of EMVision

The future of stroke care

The team are hopeful that the First Responder will hit the market around 12 to 18 months after the emu™. EMVision is showing how Australian businesses can innovate to tackle global health challenges.

Further information